Galapagos Posts 2025 Profit and Accelerates Strategic Exit from Cell Therapy

robot
Abstract generation in progress

Galapagos reported a significant turnaround in 2025, moving from an operating loss to a profit of €295.1 million, largely due to a €1.069 billion deferred income release from a collaboration. The company is strategically exiting its cell therapy business, streamlining its workforce, and focusing on immunology with promising Phase 2 data for its TYK2 inhibitor GLPG3667, while also exploring partnership opportunities. This strategic repositioning aims for business development-led growth and cash flow neutrality by late 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)